Last reviewed · How we verify
Non-Steroidal Aromatase Inhibitor
Non-Steroidal Aromatase Inhibitor is a Non-Steroidal Aromatase Inhibitor Small molecule drug developed by Borstkanker Onderzoek Groep. It is currently in Phase 3 development for Treatment of hormone receptor-positive breast cancer. Also known as: NSAI, letrozole, Femara®, anastrozole, Arimidex®.
Inhibits the enzyme aromatase, which is involved in the production of estrogen.
Inhibits the enzyme aromatase, which is involved in the production of estrogen. Used for Treatment of hormone receptor-positive breast cancer.
At a glance
| Generic name | Non-Steroidal Aromatase Inhibitor |
|---|---|
| Also known as | NSAI, letrozole, Femara®, anastrozole, Arimidex® |
| Sponsor | Borstkanker Onderzoek Groep |
| Drug class | Non-Steroidal Aromatase Inhibitor |
| Target | Aromatase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting aromatase, this drug reduces the levels of estrogen in the body, which can slow the growth of hormone receptor-positive breast cancer cells.
Approved indications
- Treatment of hormone receptor-positive breast cancer
Common side effects
- Hot flashes
- Musculoskeletal pain
- Arthralgia
Key clinical trials
- Letrozole Plus Ribociclib or Placebo as Neo-adjuvant Therapy in ER-positive, HER2-negative Early Breast Cancer (PHASE2)
- Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (PHASE3)
- A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (PHASE3)
- A Study of Single Dose of BL0175 in Postmenopausal Women (PHASE1)
- TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (PHASE2)
- PreOperative Endocrine Therapy for Individualised Care With Abemaciclib (PHASE3)
- Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (PHASE2)
- Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-Steroidal Aromatase Inhibitor CI brief — competitive landscape report
- Non-Steroidal Aromatase Inhibitor updates RSS · CI watch RSS
- Borstkanker Onderzoek Groep portfolio CI
Frequently asked questions about Non-Steroidal Aromatase Inhibitor
What is Non-Steroidal Aromatase Inhibitor?
How does Non-Steroidal Aromatase Inhibitor work?
What is Non-Steroidal Aromatase Inhibitor used for?
Who makes Non-Steroidal Aromatase Inhibitor?
Is Non-Steroidal Aromatase Inhibitor also known as anything else?
What drug class is Non-Steroidal Aromatase Inhibitor in?
What development phase is Non-Steroidal Aromatase Inhibitor in?
What are the side effects of Non-Steroidal Aromatase Inhibitor?
What does Non-Steroidal Aromatase Inhibitor target?
Related
- Drug class: All Non-Steroidal Aromatase Inhibitor drugs
- Target: All drugs targeting Aromatase
- Manufacturer: Borstkanker Onderzoek Groep — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Treatment of hormone receptor-positive breast cancer
- Also known as: NSAI, letrozole, Femara®, anastrozole, Arimidex®